Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Londamocitinib xinafoate by AstraZeneca for Asthma: Likelihood of Approval
Londamocitinib xinafoate is under clinical development by AstraZeneca and currently in Phase II for Asthma. According to GlobalData, Phase II...